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Normal release of glucagon from pancreatic islet α-cells promotes glucose mobilization,
which counteracts the hypoglycemic actions of insulin, thereby ensuring glucose
homeostasis. In treatment of diabetes aimed at rigorously reducing hyperglycemia to avoid
chronic complications, the resulting hypoglycemia triggering glucagon release from α-cells
is frequently impaired, with ensuing hypoglycemic complications. This review integrates
the physiology of glucagon secretion regulating glucose homeostasis in vivo to single α-
cell signaling, and how both become perturbed in diabetes. α-cells within the social milieu
of the islet micro-organ are regulated not only by intrinsic signaling events but also by
paracrine regulation, particularly by adjacent insulin-secreting β-cells and somatostatin-
secreting δ-cells. We discuss the intrinsic α-cell signaling events, including glucose
sensing and ion channel regulation leading to glucagon secretion. We then discuss the
complex crosstalk between the islet cells and the breakdown of this crosstalk in diabetes
contributing to the dysregulated glucagon secretion. Whereas, there are many secretory
products released by β- and δ-cells that become deficient or excess in diabetes, we
discuss the major ones, including the better known insulin and lesser known somatostatin,
which act as putative paracrine on/off switches that very finely regulate α-cell secretory
responses in health and diabetes. Of note in several type 1 diabetes (T1D) rodent models,
blockade of excess somatostatin actions on α-cell could normalize glucagon secretion
sufficient to attain normoglycemia in response to hypoglycemic assaults. There has been
slow progress in fully elucidating the pathophysiology of the α-cell in diabetes because
of the small number of α-cells within an islet and the islet mass becomes severely
reduced and inflamed in diabetes. These limitations are just now being surmounted by
new approaches.
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OVERVIEW
Glucagon is a counter-regulatory hormone that counteracts
insulin by promoting glucose mobilization in liver through
glycogenolysis and gluconeogenesis (Dunning and Gerich, 2007;
Quesada et al., 2008). Normally, low glucose levels trigger
glucagon release from α-cells to abrogate the deleterious effects
of insulin-induced acute hypoglycemia (Cryer, 2002; Dunning
and Gerich, 2007; Quesada et al., 2008). As described below,
even the very question of whether low blood sugar directly trig-
gers glucagon release remains unresolved. In Type 1 (T1D) and
Type 2 diabetes (T2D), glucagon secretion from α-cells become
dysregulated (Gerich et al., 1973; Bolli et al., 1983; Butler and
Abbreviations: Type 1 diabetes, T1D; Type 2 diabetes, T2D; glucagon-like
peptide-1, GLP-1; streptozotocin, STZ; BioBreeding, BB; glucagon receptor-null
mice, Gcgr−/− ; insulin-like growth factor, IGF; voltage-dependent Ca2+ chan-
nel, VDCC; ATP-dependent K+ channel, KATP channel; voltage-dependent K+
channel, Kv channel; AMP-activated protein kinase, AMPK; Per-arnt-sim (PAS)
domain-containing protein kinase, PASK; mouse insulin promoter- green fluores-
cent protein, MIP-GFP; γ-aminobutyric acid, GABA; somatostatin receptor type-2,
SSTR2.
Rizza, 1991; Cryer, 2002; Dunning and Gerich, 2007; Quesada
et al., 2008). In early diabetes, α-cells hypersecrete during meals
(Butler and Rizza, 1991; Dunning and Gerich, 2007; Quesada
et al., 2008) causing excessive release of glucose, resulting in
hyperglycemia and eventually consequent chronic complications
(blindness, kidney, heart failure, and neuropathy). As diabetes
progresses, becoming more severe, more β-cells die and α-cells
suffer from “hypoglycemic blindness” (perhaps partly due to
increased sensitivity to exogenous insulin), becoming sluggish
in response to low glucose, exacerbating life-threatening acute
hypoglycemic episodes, responsible for ∼5% of mortality due to
diabetes (Gerich, 1988; Cryer, 2002). About 20 million people
world-wide are at risk of developing hypoglycemia, of which 9
million reside in North America. It is well known that on average,
insulin-treated diabetic patients have 2–3 hypoglycemic events
per week. Hypoglycemia is one of the key acute complications of
insulin therapy in diabetes treatment.
In addition to increased α-cell sensitivity to insulin, chronic
hyperglycemia plays an important role in dysregulation of α-cells
(Shi et al., 1996) but no effective treatment has been developed to
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increase (or regulate) glucagon secretion to combat hypoglycemic
attacks. The primary reason for the lack of evidence is the very
low-yield isolation (∼20% of islet cells) and unreliable identifica-
tion of islet α-cells, which severely impairs accuracy and efficiency
in studying α-cell biology. In contrast, tremendous efforts have
been directed at studying islet β-cell biology (Henquin et al.,
2003; Rorsman and Renstrom, 2003), leading to development of
effective drug compounds to stimulate insulin secretion (Moller,
2001) and improved islet transplantation strategies (Shapiro et al.,
2000). The biggest obstacle in islet transplantation is limited
supply of donor islets, thus great efforts have been directed at
strategies of “pure” β-cell replacement derived from stem cells
(Ramiya et al., 2000) or surrogates (Newgard, 1994)—the panacea
of the “cure” for diabetes! Of note, not only β-cell but also α-cell
mass in transplanted islets are reduced, with surviving α-cells
suffering from defective response to glucose and incretin hor-
mone glucagon-like peptide-1 (GLP-1) (Newgard, 1994; Gupta
et al., 1997; Paty et al., 2002; Zhou et al., 2008; Rickels et al.,
2009).
In spite of severe technical restrictions, the importance of α-
cell in islet biology, pathobiology and implication on cell replace-
ment therapy of T1D have been the impetus of the vigorous thrust
of key labs to examine the intimate cross-talk between islet cells
(Ishihara et al., 2003), α-cell glucose-sensing (Heimberg et al.,
1996), α-cell ion channels (Kanno et al., 2002), and glucagon exo-
cytosis (Barg, 2003) not only in rodent models, but also in human
α-cells (MacDonald et al., 2007; Rorsman et al., 2008). Since, islet
α-cell mass remains relatively intact even in advanced stages of
diabetes (Stefan et al., 1982; Rahier et al., 1983), native α-cells
lend itself to pharmacological intervention (Dunning et al., 2005;
Dunning and Gerich, 2007). However, the precise molecular reg-
ulators by which glucose couples to secretory components of α-
cells remain hotly debated (Gromada et al., 2007; Quesada et al.,
2008). How these coupling mechanisms become dysregulated in
diabetes albeit recently postulated (switch on/off hypothesis), the
precise underlying cellular basis is unknown.
THE ROLE OF GLUCAGON IN DIABETES
Roger Unger postulated that diabetes is caused by insulin defi-
ciency (amount or effect) and glucagon presence, or excess
(Unger et al., 1970). The main problem with Unger’s hypothe-
sis was that diabetes can be induced in animals either by selective
chemical destruction of insulin producing β-cells, or by total pan-
createctomy, which removes both β-cells and glucagon-producing
α-cells, and diabetes occurs in both protocols irrespective of
whether the α-cells have been removed by pancreatectomy. If
glucagon is essential for development of diabetes, one would have
expected that total pancreatectomy would not induce diabetes.
But that was not the case. At that time, the laboratories that were
best known formeasuring glucagon in plasmawere those of Roger
Unger in Dallas Texas, Pierre Lefebvre in Liege, and Roger Assan
in Paris. All three laboratories reported that after pancreatectomy
in dogs, plasma glucagon could not be detected. A few years ear-
lier, two Nobel Prize winners, DeDuve and Sutherland, showed
that extracts from the mucosa of the dog’s stomach have a hyper-
glycemic effect (Sutherland and De Duve, 1948). This could have
been glucagon, but quantitative glucagon assay did not yet exist.
To our surprise and in contrast to other laboratories, we could still
detect plasma glucagon in insulin-infused depancreatized dogs. If
insulin treatment was discontinued, glucagon skyrocketed within
a week after pancreatectomy (Vranic et al., 1974). These results
created a great deal of excitement because it was contrary to the
dogma that depancreatized dogs did not have any glucagon in
the plasma. This led to the stunning discovery, that a pancreatic
hormone can be produced in large amounts outside its original
endocrine gland. Over the next 10 years, using tracer methods to
measure glucose fluxes, biochemical, histological, immunological
methods, electron microscopy, and purifying gastric glucagon to
homogeneity, it was determined beyond all doubt that the pari-
etal mucosa of the dog stomach can synthesize and secrete true
glucagon (Morita et al., 1976; Doi et al., 1979).
When stomach glucagon was purified to homogeneity, its
effect on isolated liver cells in-vitro was quantified. The effects
of the extracts were identical to those of pancreatic glucagon.
Now, it was not surprising by measuring glycogenolysis, gluco-
neogenesis, production of lactate and pyruvate, and concentra-
tion of cAMP, that following pancreatectomy in dogs, diabetes
is as severe as with the selective destruction of the β-cells (Doi
et al., 1979). Another stunning finding was that in the gas-
tric mucosa of a depancreatized dog that was maintained on
insulin by for 5 years, there was a large hyperplasia of α-cells,
and a large amount of glucagon in the dog’s stomach. By elec-
tron microscopy of the parietal mucosa of the stomach looked
like a glucagon-producing endocrine gland (Ravazzola et al.,
1977). It was demonstrated with labeled tryptophan, leucine, and
s-methionine, the specific biosynthesis of glucagon in mucosa
pieces of the stomach (Hatton et al., 1985). These findings chal-
lenged classical views of endocrinology and provided further
proof that one hormone is not necessarily produced in only one
endocrine gland. Furthermore, the amount of glucagon-like pep-
tides that are secreted exclusively from the gastro-intestinal tract
was quantified (Mojsov et al., 1987). High glucagon plasma lev-
els in the depancreatized dogs were also confirmed by others
(Matsuyama and Foa, 1974). Their regulation of extrapancre-
atic glucagon release was different than that from the pancreas
(Luyckx and Lefebvre, 1983). True glucagon was localized exclu-
sively in the stomach because pancreatectomy plus gastrectomy
virtually removed glucagon from plasma (Muller et al., 1978). The
most extensive factors that control gastric glucagon release were
ascertained by using a unique model of isolated-perfused dog
stomach (Lefebvre and Luyckx, 1977). Arginine elicited rapid gas-
tric glucagon release. This glucagon release was almost completely
abolished by somatostatin. It was not affected by hypoglycemia
alone, but was reduced by 40% when hyperglycemia was con-
comitant with hyperinsulinemia. Thus, insulin is needed for
hyperglycemia to inhibit gastric glucagon secretion. Perfused dog
stomach provides a unique tool for investigating α-cell function
in absence of endogenously released insulin. In addition, they
also reported that immune-neutralization of insulin in the blood
perfusing the stomach doubled the glucagon release, and thus fur-
ther confirmed the role of insulin in controlling α-cell secretion
(Lefebvre and Luyckx, 1978). These early observations in the dog
stomach are relevant in the studies of pancreatic slices, of strep-
tozotocin (STZ) and BioBreeding (BB) diabetic rats, which will
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be reported later in this review. In contrast to dogs, in totally
depancreatized humans, there is only a negligible amount of
plasma glucagon, and in contrast to depancreatized dogs, in dep-
ancreatized humans, diabetes is very mild (Barns et al., 1977;
Muller et al., 1979; Boden et al., 1980; Holst et al., 1983). Thus,
the discovery of extra-pancreatic glucagon led to a much better
understanding of the role of glucagon in physiology and diabetes.
Glucagon-like peptides are detected in the brain (Tager et al.,
1980; Tominaga et al., 1981; Hatton et al., 1982) and that stim-
ulated interest in this field. The discovery of extra-pancreatic
glucagon and quantification of release of glucagon-like peptides
from the intestine, also stimulated research in the field of GLP-1
that is co-encoded in the glucagon gene as a potent stimulator of
insulin release (Mojsov et al., 1987; Drucker, 2005).
Recently, studies in glucagon receptor-null mice (Gcgr−/−)
indicate that glucagon mediates the metabolic consequences of
insulin lack (Lee et al., 2011). In these mice, which exhibit no
response to glucagon at any concentration, destruction of β-cells
did not result in any of the diabetic abnormalities thought to be
caused by insulin deficiency. Destruction of β-cells in wild-type
controls resulted in the familiar catabolic consequences of insulin
deficiency, with death due to ketoacidosis within 6 weeks, whereas
in the Gcgr−/− mice, none of the clinical or laboratory manifes-
tations of insulin deficiency was detected. The insulin-deficient
Gcgr−/− mice did not become hyperglycemic or hyperketone-
mic, and their livers exhibited no increase either in phosphor-
cAMP response element-binding protein (p-CREB); a mediator
of glucagon action (Altarejos and Montminy, 2011) or in the glu-
coneogenic enzyme phosphoenolpyruvate carboxykinase, both of
which are elevated in uncontrolled diabetes. Unquestionably, this
exciting new finding indicates an important role of glucagon in
diabetes. The interesting question is whether there are compen-
satory mechanisms that occur in knock-out rodents that replace
the action of insulin, such as increased insulin-like growth factor
(IGF)-1 or increased sensitivity of insulin receptors to IGF-1. It
is also difficult with the methods presently used to ascertain that
insulin has been completely removed. One could speculate that
some knock-outs procedures may alter the physiology of insulin-
glucagon interactions, and may reflect a metabolic system not
seen in physiology or in diabetes.
THE CELLULAR MECHANISM OF α-CELL GLUCAGON
SECRETION
The cellular machinery that controls glucagon secretion from
α-cells is perhaps surprisingly similar to that which regulates
insulin secretion from β-cells (Figure 1). Glucagon-containing
secretory granules, like those containing insulin, exist in what
can be defined functionally as “reserve” and “releasable” pools.
Like the secretion of insulin from β-cells, the exocytotic release of
glucagon is triggered by Ca2+ entry through voltage-dependent
Ca2+ channels (VDCCs) (Barg, 2003; Altarejos and Montminy,
2011). An increase in glucose decreases intracellular Ca2+ in
α-cells (both isolated ones and within intact islets) (Olofsson
et al., 2004; Cabrera et al., 2006; MacDonald et al., 2007; Vieira
et al., 2007), although, this has been recently questioned in α-
cells identified through α-cell-specific expression of fluorescent
proteins (Le Marchand and Piston, 2010). Regardless, in response
to increases in Ca2+, glucagon granule exocytosis is mediated
by the action of exocytotic SNARE proteins that, like in β-cells,
consists of a multi-protein complex including SNAP-25 and syn-
taxin 1A (Andersson et al., 2011). The insulin and glucagon
secreting islet cells also share a principal exoctotic Ca2+ sensor,
synaptotagmin VII (Gustavsson et al., 2009), although, as in β-
cells (Gauthier and Wollheim, 2008) the involvement of other
synaptotagmin isoforms has not been ruled out. The compli-
ment of ion channels expressed in α-cells mirrors those found in
β-cells. ATP-dependent K+ (KATP) channels, voltage-dependent
K+ (Kv) channels, and VDCCs are all present in both α- and
β-cells (Ronner et al., 1993; Bokvist et al., 1999; Suzuki et al.,
1999; MacDonald et al., 2007; Ramracheya et al., 2010; Spigelman
et al., 2010). While the K+ channel isoforms may be largely the
same in the two cell types, the relative contribution of VDCC
isoforms is somewhat different in α-cells, with a greater con-
tribution of P/Q-type channels in human α-cells [the details of
α-cell Ca2+ signaling have been recently extensively reviewed
(Rorsman et al., 2012)]. Additionally, voltage-dependent Na+
channels are thought to play a more prominent role in glucagon,
rather than insulin, secretion (Gromada et al., 1997; Barg et al.,
2000; Gopel et al., 2000; Ramracheya et al., 2010) and glucagon
release is sensitive to the Na+ channel inhibitor tetrodotoxin
(Gopel et al., 2000; Gromada et al., 2004; MacDonald et al.,
2007).
It is not surprising then that pancreatic α-cells are electrically
excitable and, like β-cells, use their electrical activity to couple
changes in glucose to the regulation of glucagon release (Rorsman
and Hellman, 1988; Gromada et al., 1997; Yoshimoto et al.,
1999; Barg et al., 2000). Looking at this excitatory and exocytotic
machinery alone however, is becomes difficult to explain how glu-
cose inhibits, rather than stimulates, α-cell glucagon secretion.
Understanding how the glucagon secretory machinery is regu-
lated by signals both intrinsic and extrinsic to the α-cell will be
necessary to elucidate the exact mechanism of glucose-regulated
glucagon secretion. Indeed, there are already hints that the exci-
tatory machinery in α-cells is regulated in a manner opposite to
that of β-cells: for example membrane depolarization is capable
of turning off a number of the ion channels involved in α-cell
electrical activity that are activated under similar conditions in
β-cells (Ramracheya et al., 2010; Spigelman et al., 2010); and hor-
monal signals, notably GLP-1, activates Ca2+ currents in β-cells
(Salapatek et al., 1999) but inhibits these in α-cells (De Marinis
et al., 2010). Thus, elucidating not only the pieces of machin-
ery that control glucagon secretion, but how these are regulated
will provide novel insight into the physiological mechanism for
glucose-regulated glucagon release.
CAN GLUCOSE REGULATE GLUCAGON SECRETION DIRECTLY?
This question has been a matter of debate for many years. Based
solely on studies of dispersed or purified α-cells (Pipeleers et al.,
1985; Ishihara et al., 2003; Olsen et al., 2005; Le Marchand and
Piston, 2010), the answer would seem to be no, since under
these conditions glucose stimulates glucagon secretion. One must
be quite careful in the interpretation of such studies however,
since properties of both dispersed α- and β-cells are quite dif-
ferent than those in intact islets. For example, the presence of
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FIGURE 1 | Pancreatic endocrine cells are regulated by intrinsic and
paracrine signals in response to glucose. At basal glucose levels
pancreatic β-cells (A, left) are electrically inactive, owing to their open
ATP-sensitive K+ (KATP) channels and resultant hyperpolarized membrane
potential, and thus do not secrete insulin. In contrast, α-cells in the presence
of low glucose (A, right) are electrically active, due to a relatively elevated
ATP/ADP ratio (even at low glucose). This results in closure of most, but
perhaps not all, KATP channels and a depolarized membrane potential that
allows action potential firing mediated by a combination of voltage-dependent
Na+, Ca2+ (VDCC), and K+ (Kv) channels. Entry of Ca2+ through VDCCs
triggers the exocytosis of glucagon-containing secretory granules. When
plasma glucose is increased (B), glucose enters pancreatic islet cells through
plasma membrane glucose transporters (GLUT) where it is metabolized
through glycolysis and mitochondrial oxidative metabolism. This results in
increase in the intracellular ATP/ADP ratio (in the case of α-cells, a further
increase) and closure of KATP channels. In the β-cell (B, top left) this results in
membrane depolarization and firing of action potentials that, in combination
with additional mitochondrial signals, results in the exocytosis of
insulin-containing granules. In α-cells, further closure of KATP channels may
further depolarize the membrane and lead to the depolarization-dependent
inactivation of Na+ channels and VDCCs. Glucagon secretion is also inhibited
by paracrine factors secreted from β-cells and pancreatic δ-cells. These
signals may interact with putative α-cell metabolic sensors (i.e., PASK and
AMPK) to produce the physiological suppression of glucagon secretion.
functional gap junction connections is recently proposed as nec-
essary for the efficient suppression of glucagon secretion (Ito
et al., 2012). These of course would be lost upon dispersion
and purification of α-cells. Within α-cells, glucose certainly has
metabolic effects (Detimary et al., 1998). While ATP levels may
be high under low glucose conditions, studies using the cell-
targeted ATP-sensor luciferase demonstrate a further increase
(by 15%) in α-cell ATP in response to glucose (Ishihara et al.,
2003; Ravier and Rutter, 2005). Recent evidence has implicated
α-cell resident metabolic sensing in the control of glucagon
secretion, and in the pathophysiology of glucagon secretion in
diabetes through AMP-activated protein kinase (AMPK) (Leclerc
et al., 2010) and Per-arnt-sim (PAS) domain-containing protein
kinase (PASK) (da Silva Xavier et al., 2011). Glucose-dependent
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inhibition of glucagon secretion was associated with an inhibition
of AMPK activity, while forced activation of AMPK stimulated
glucagon secretion. This study (Leclerc et al., 2010) suggests then
that although the baseline ATP level may be high, a glucose-
stimulated rise in ATP (and drop in ADP and AMP) can indeed be
sensed within the α-cell. This is particularly interesting since the
AMPK pathway generally acts as a “master regulator” of energy
metabolism. While the idea that AMPK activation may be bene-
ficial in diabetes may seem at odds with the glucagon-stimulating
effects of AMPK activation, this must be considered in the context
of the activity of upstream AMPK regulators which themselves
may be regulated by glucose in α-cells. At this time there is lit-
tle or no information about the up- or down-stream regulators
of AMPK in α-cells, although, this is currently an area of grow-
ing interest in the context of insulin secretion [reviewed in ref.
Fu et al. (2012)]. Thus, the α-cell may indeed be capable of
responding to intrinsic metabolic signals, and integrating these
inputs with extrinsic paracrine signals in the physiologic control
of glucagon secretion.
ARE α-CELL KATP CHANNELS INVOLVED IN THE REGULATION OF
GLUCAGON SECRETION?
The activity of α-cell KATP-channels is thought to contribute to
the control of glucagon secretion (Ronner et al., 1993; Bokvist
et al., 1999; Gromada et al., 2004; MacDonald et al., 2007). A role
for KATP channels in the regulation of glucagon secretion is sup-
ported by the reduced glucagon secretion under low-glucose con-
ditions seen in mice lacking functional KATP-channels (Gromada
et al., 2004; Munoz et al., 2005; MacDonald et al., 2007), where
increasing glucose stimulated glucagon secretion similar to that
observed in purified α-cells. Although, α-cell KATP channels are
thought to be ∼94% inhibited already at low glucose conditions
(Barg et al., 2000; Gopel et al., 2000; Gromada et al., 2004; Olsen
et al., 2005), perhaps explaining the ability of α-cells to generate
action potentials under this condition, experiments titrating KATP
channel activity revealed a bell-shaped curve where glucagon
release was inhibited by either toomuch or too little KATP conduc-
tance (MacDonald et al., 2007; Rorsman et al., 2008). However,
it should be recognized that all KATP-channel measurements in
α-cells suggest that the effect of glucose on overall channel activ-
ity may be smaller than that seen with pharmacologic agents
(Gromada et al., 2004; Olsen et al., 2005). Nonetheless, given the
low input resistance of α-cells, small changes in KATP channel
activity may be functionally relevant.
Interestingly, work in mice expressing GFP under the con-
trol of the mouse insulin promoter (MIP-GFP mice) showed
that α-cell KATP channels are more sensitive to ATP than are
those in β-cells (Leung et al., 2005, 2006). In those reports, we
showed that insulin reduces the sensitivity of α-cell KATP chan-
nels to ATP relatively more so than β-cell KATP channels, and this
was by its actions on the insulin receptor-phosphatidylinositol
3-kinase signaling pathway. This may account for the fact that
most (92%) of α-cell KATP channels are closed at 1mM ATP.
Since, the ATP concentration inside α-cell is >1mM at low glu-
cose (Vieira et al., 2007; Huang et al., 2011b), this could account
for the large proportion of KATP channels that are closed in
α-cells at low glucose and perhaps indicates that changes in
other cytosolic factors [i.e., phospholipids (Baukrowitz et al.,
1998; Shyng and Nichols, 1998) and glucose metabolites (Duchen
et al., 1993; Mertz et al., 1996; Schuit et al., 1997; Dufer et al.,
2002)] can modulate KATP channel sensitivity to ATP. The fac-
tors and signaling mechanisms that control α-cell KATP channel
sensitivity to ATP are not well understood, although, regula-
tion by paracrine factors may represent one such mechanism
that could bridge the divide in understanding the interplay
between paracrine and intrinsic factors controlling glucagon
secretion.
COMPLEX CROSSTALK BETWEEN ISLET CELLS
Release of islet hormones is regulated not only by direct actions
of glucose and other nutrients, but also indirectly and potently by
paracrine factors secreted by adjacent islet cells. The current body
of knowledge shows that islet cells profoundly modulate each
other’s secretory functions by very complex paracrine and even
autocrine pathways (Gaisano and Leung, 2008). High glucose
stimulates β- ad δ-cell secretion while inhibiting α-cell secre-
tion, whereas low glucose stimulates α-cell secretion directly or
indirectly, but inhibits other islet cells (Dunning and Gerich,
2007; Quesada et al., 2008). Since insulin reduces KATP chan-
nel sensitivity to ATP in α-cells more so than β-cells (Leung
et al., 2006), the sequential glucose-insulin paracrine control on
α-cells via modulation of α-cell KATP channel sensitivity to ATP
blockade likely becomes distorted in T2D, which would con-
tribute to the dysregulated glucagon secretion. Indeed, glucagon
secretion has long been known to be inhibited by insulin (Le
Marchand and Piston, 2010; Andersson et al., 2011), but just
now shown to be mediated via the α-cell-specific expression of
the insulin receptor using a knockout strategy (Kawamori et al.,
2009). Other β-cell secretory products also inhibit glucagon secre-
tion, including Zn2+ (Ishihara et al., 2003; Franklin et al., 2005)
and γ-aminobutyric acid (GABA) co-released from dense-core
insulin granules and synaptic vesicles (GABA only) (Franklin and
Wollheim, 2004; Wendt et al., 2004), together asserting redun-
dant paracrine inhibition of glucagon secretion (Gromada et al.,
2001; Cejvan et al., 2003; Franklin and Wollheim, 2004; Wendt
et al., 2004; Franklin et al., 2005; Ludvigsen et al., 2007; Plöckinger
and Strowski, 2007; Hauge-Evans et al., 2009; Kawamori et al.,
2009). L-glutamate released from α- (Cabrera et al., 2008) and
β-cells (Hayashi et al., 2003) stimulates GABA secretion from
β-cells under low glucose, and acts directly on α-cells to stim-
ulate glucagon release, thus asserting counteracting paracrine
inhibitory and autocrine stimulatory actions on α-cells. Glucagon
secreted by α-cells exhibits paracrine stimulatory action on β-cells
and autocrine stimulation of α-cell glucagon secretion (Ma et al.,
2005).
BREAKDOWN IN ISLET CROSSTALK IN DIABETES
A major acute complication of diabetes is a defective response
of glucagon, catecholamines and glucocorticoids to insulin-
induced hypoglycemia coined “glucose blindness.” This occurs
more frequently with antecedent hypoglycemia and hypoglycemia
unawareness, and it is in part due to poor counterregulatory
responses (Bolli et al., 1983; Dagogo-Jack et al., 1993; The
Diabetes Control and Complications Trial Research Group, 1993;
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Fanelli et al., 1994). It is particularly important that some diabetes
patients have increased risk of hypoglycemia during insulin treat-
ment therapy (White et al., 1983). The threat of hypoglycemia
has increased since the treatment for diabetes has aimed for tight
blood glucose control to decrease the risk of diabetic compli-
cations. In order to avoid hypoglycemia, many diabetic patients
reduce their blood glucose control. Thus, hypoglycemia is a
limiting factor for proper control of glycemia. Therefore, it is
important to develop a treatment strategy that would decrease
the risk of hypoglycemia. The defect of glucagon and epinephrine
responses to hypoglycemia in diabetes is puzzling because both
counterregulatory responses are normal or even excessive dur-
ing some stresses, such as moderate and strenuous exercise, both
in dogs and humans (Orci et al., 1976; Wasserman et al., 1985;
Marliss and Vranic, 2002). We showed that although in each islet
the number of glucagon cells is greatly increased, the total amount
of glucagon in the pancreas remains unchanged because of the
reduction in the number of islet cells. Clearly, alloxan or STZ
destroys not only β-cells, but they also reduce the total num-
ber of islet cells. It is well known that the release of glucagon
by the pancreas is inhibited by both insulin and somatostatin;
and in diabetes, defects in the release of these islet paracrine hor-
mones contribute to the perturbation of glucagon release from
α-cells.
Thus, the physiological regulation of glucagon secretion is
complex (Figure 1). Under conditions of hypoglycemia the α-cell
is electrically active, in part due to a high basal ATP (and con-
sequent inhibition of much of the KATP currents), which allows
opening of Ca2+ channels and glucagon exocytosis. At high
glucose, paracrine inputs from both β- and δ-cells are crucial
physiological suppressors of glucagon release through actions
on the α-cell electrical and secretory machinery. Although con-
troversial, metabolic sensing pathways intrinsic to the α-cell
likely contribute to the suppression of glucagon release either
directly, by inhibiting the α-cell ion channels and exocytotic
machinery, or indirectly by modulating the cellular response
to paracrine signals. As such, glucagon release is the result
of an integrated α-cell response to external and internal cues.
A breakdown in these mechanisms in diabetes likely con-
tributes to hyperglucagonemia and impaired counterregulatory
responses.
DEFECTIVE SWITCHES OF INSULIN AND
SOMATOSTATIN
DEFECTIVE INSULIN SWITCH
In T1D, there is a lack of decrement changes in intraislet insulin
occurring which has been postulated to account for the defective
glucagon counter-regulation to hypoglycemia. α-cell sensitivity
during hypoglycemia improves when normoglycemia is achieved
by chronic phloridzin treatment, but not by insulin treatment
in diabetic rats (Shi et al., 1996). This is partly due to insulin
inhibition of glucagon synthesis and release (Liu et al., 1992;
Amatruda and Livingston, 2003). This thinking became refined
in two in vivo reports elegantly demonstrating the insulin “switch
on-off” actions on α-cell and “glucose blindness” in glucagon
secretory response in T1D (and T2D) (Paty et al., 2002; Hope
et al., 2004). These reports showed the ability of low glucose
to stimulate α-cell secretion requires initial increase in insulin
levels (switch on) followed by insulin deprivation (switch off)
in presence of low glucose. The intraislet insulin “switch off”
hypothesis has however been further refined to suggest that it
may not be due to insulin per se (Hope et al., 2004; Zhou
et al., 2004), but rather Zn2+ (bound and co-released with
insulin) (Zhou et al., 2007); but this notion was also challenged
(Ravier and Rutter, 2005). Thus, the precise cellular/molecular
mechanisms of insulin and Zn2+ switch on-off actions remain
unclear.
DEFECTIVE SOMATOSTATIN SWITCH
Plasma somatostatin, pancreatic prosomatostatin mRNA and
somatostatin protein levels are increased in diabetic humans (Orci
et al., 1976), dogs (Rastogi et al., 1990), and rodents (Shi et al.,
1996; Inouye et al., 2002), which may be due to insulin defi-
ciency (Papachristou et al., 1989; Rastogi et al., 1990), although,
insulin treatment did not prevent the abundance of somatostatin-
containing δ-cells in human diabetic pancreata (Patel, 1999),
and/or absolute or relative glucagon excess within the pancreatic
islet might also lead to a compensatory increase in somato-
statin (Patel, 1999). In T1D, upper-gut somatostatin, the major
source of circulating somatostatin, is also increased (Papachristou
et al., 1989; Patel, 1999). It is generally believed that somatostatin
only plays a minor role in inhibiting the α-cell in non-diabetic
animals or humans. Global somatostatin knock-out increased
nutrient stimulated, but not basal glucagon secretion, compared
with wild-type mice, in-vivo and in isolated islets, suggesting
a role of locally released somatostatin on stimulated, but not
basal insulin secretion (Hauge-Evans et al., 2009). Similarly, iso-
lated islets from somatostatin receptor type-2 (SSTR2) knock-out
mice showed 2-fold greater stimulated glucagon secretion than
wild type mice (Strowski et al., 2000). In human isolated islets
a dose-dependent reversal of SSTR2 antagonist induced sup-
pression of glucagon secretion was achieved by using the same
SSTR2 as the current study (Singh et al., 2007). Thus, using the
SSTR2 antagonists may appear to also be relevant to humans.
Sincemost β-cells have been destroyed, somatostatin becomes the
main paracrine inhibitor of the α-cell in diabetes. That is why it
was of particular interest that in diabetic dog islets, the ratio of
somatostatin to glucagon is markedly increased. An acute insulin
injection increased this ratio further. This was the first demon-
stration that part of the defective mechanism in hypoglycemia
may reflect alterations of this ratio in diabetes (Rastogi et al.,
1990). One could hypothesize that in diabetes, in absence of the
tonic effect of insulin, islet α-cells are oversensitive to insulin and
are exposed to increased somatostatin (Papachristou et al., 1989;
Shi et al., 1996). Somatostatin is increased in the pancreas and also
in blood. The major part of the concentration of somatostatin
in blood is due to somatostatin release from the gut. Thus, the
increase in local somatostatin and release of somatostatin deliv-
ery to the pancreas may both play a role in diabetes (Figure 2).
It was previously demonstrated that in perifused islets and in
infused isolated pancreas that the SSTR antagonist can greatly
increase the response of α-cells to arginine. However, responses
to insulin-induced hypoglycemia have not been tested. In order
to test the hypothesis about the importance of somatostatin in
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FIGURE 2 | In the normal physiology, the α-cell is under the tonic
inhibitory influence of insulin and therefore somatostatin inhibition of
α-cell may be of minor or no importance (Singh et al., 2007). This is in
contrast to diabetic islets in diabetes, where α-cell may be more sensitive
to insulin and in addition, both circulating and pancreatic somatostatin, are
increased. It is generally believed that hypoglycemia is a strong stimulator
of glucagon release from the α-cell. However, in islets in-vitro the effect of
hypoglycemia is not consistent. This difference may reflect the fact that
between in-vitro and in-vivo systems, in-vivo the islets have abundant blood
flow, which brings to the islet other factors such as amino acids (i.e.,
arginine) that can stimulate glucagon release. We hypothesize therefore,
that hypoglycemia has an effect only when amino acids or other
substances found in blood, are present. In absence of the tonic effect of
insulin, somatostatin is the only endogenous inhibitor of glucagon release
and insulin exerts a strong inhibitory effect on the α-cell. Therefore, when
an antagonist blocks the α-cell receptors, despite the inhibitory effect of
injected insulin, the α-cell can release normal amounts of glucagon (Vranic,
2010). The figure is modified from that we previously reported (Vranic,
2010).
diabetic rats, a specific antagonist (SSTR2) of the somatostatin
receptor of α-cells was injected. It was demonstrated that infu-
sion of this antagonist can fully normalize glucagon responses
to insulin-induced hypoglycemia in diabetic rats [Figure 3, from
ref. Yue et al. (2011)]. A patent (Vranic et al., 2009) was filed
for the prevention of hypoglycemia, and hope that the results
obtained in the rats can be applied to human diabetics and
thereby, diminish or prevent hypoglycemic episodes. This could
permit diabetic patients to adhere more strictly to an inten-
sive insulin treatment and lessen the risk of diabetic complica-
tions.
Most importantly, infusion of the SSTR2 antagonist in absence
of insulin did not affect the blood concentration of insulin,
glucagon, epinephrine, or blood-sugar (Yue et al., 2011). The
efficacy of the SSTR2 antagonist with two different doses of
the antagonist and of insulin was tested. It was found that
the most consistent results were obtained with 10 units/kg of
insulin and 3000 nmol/kg/h of SSTR2 antagonist (Figure 3) (Yue
et al., 2011). It is particularly interesting that in normal rats
the antagonist did not improve or even decrease the response
of glucagon to insulin-induced hypoglycemia. One could specu-
late that in normal rats, the high doses of antagonist even have
some agonist properties, and confirmed that in normal rats,
somatostatin is not a major inhibitor of hypoglycemia-induced
glucagon release. The response of corticosterone was also nor-
malized. Corticosterone in contrast to glucagon is important
for hypoglycemias of longer duration, since the effects of corti-
sol are mainly exerted through genetic mechanisms. This could
also be of importance for glucagon release because cortisol has
some effect on the α-cells’ control. Interestingly, delivery of the
SSTR2 antagonist did not further increase pancreatic glucagon
and somatostatin, or plasma somatostatin.
One of the key questions was whether the SSTR2 antagonist
can actually prevent hypoglycemia. On the first day insulin alone,
and on the second day, either insulin alone or an infusion of
antagonist was started in the same rat, before the insulin-induced
hypoglycemia (Vranic et al., 2009). The reason for such designs
is that even one episode of hypoglycemia sensitizes the endocrine
and metabolic system so that you would expect that on the sec-
ond day the rats would need a different amount of insulin. In
order to avoid this problem, diabetic rats were injected for 3
days with insulin, in order to avoid further effect of antecedent
hypoglycemia. After the injection of insulin, rats became hypo-
glycemic, but with the SSTR2 antagonist, hypoglycemia was
avoided. Without the antagonist, glucagon response was abol-
ished, but with the antagonist, glucagon response was restored
(Yue et al., 2010). These STZ-induced diabetic rats were not
treated with insulin since they still have some residual insulin in
the blood and in the pancreas. In contrast, BB rats are totally
insulin-deprived, thus requiring insulin treatment, and there-
fore this model is more similar to human T1D; both caused
by immune destruction of the β-cells. The in-vivo to in-vitro
responses to hypoglycemia and arginine in controls and in dia-
betic BB rats were compared (Qin et al., 2012). In the in-vivo
experiments, the glucose was clamped at 2.9mmol/L. In contrast
to the controls, the glucagon response was greatly diminished,
but it was normalized during the infusion of the SSTR2 antag-
onist. With glucagon response normalized, the BB rats did not
need glucose infusion to maintain the clamp, while without
the antagonist they needed a large amount of glucose infused
because of the glucagon deficiency. Interestingly, we used for the
first time pancreatic slices to assess the effect of hypoglycemia
and arginine. Surprisingly, hypoglycemia per se did not increase
glucagon release. However, glucagon release was enhanced when
arginine was infused (Qin et al., 2012). The difference between
in-situ and in-vitro experiments is that pancreatic slices are not
controlled by the nervous system and are not exposed to hor-
mones or metabolites (such as, arginine) that stimulate glucagon
release.
It was questioned whether somatostatin plays a role dur-
ing hypoglycemia because somatostatin-secreting δ-cells are
downstream of glucagon-secreting α-cells in the islet microcir-
culation of non-diabetic rats (Samols et al., 1988). However,
δ-cells in diabetic rats are also distributed in central portions
of islet cells because the architecture of islet cell type is altered
(Adeghate, 1999), suggesting that paracrine actions of islet hor-
mones are altered in diabetes such that somatostatin release
upstream of α-cells may affect glucagon secretion. The arrange-
ment of human endocrine islet cells is likewise more disperse
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FIGURE 3 | In diabetic (D) rats, plasma glucagon increases only
marginally during a glucose clamp at 2.5mmol/L. (A) Hypoglycemia
was induced with 10 units/kg of regular insulin was injected
subcutaneously. 3000nmol/kg/h of somatostatin receptor type 2 antagonist
(SSTR2a) was infused intravenously starting 30min before insulin injection
(D + SSTR2a). (B) The response of glucagon to hypoglycemia was the
same as in normal (N) rats. (C) The data is also shown as area under the
curve (AUC) analysis. The data is modified from that we reported in ref.
Yue et al. (2011). The SSTR2a is highly specific for glucagon and only
marginally for insulin, and it’s structure is H-Fpa-cyclo[DCys-PAL-DTrp-Lys-
Tle-Cys]-Nal-NH2 (Yue et al., 2011). ∗P < 0.002D vs. N; †P < 0.05D vs.
D+SSTR2a.
throughout the islet, which provides evidence for the proximity
of δ-cells and α-cells (Cabrera et al., 2006; Braun et al., 2009; Kim
et al., 2009). Furthermore, paracrine signaling may also occur
via diffusion within the islet interstitium, independent of blood
flow.
The remaining question to be answered is to explore factors
in blood that are necessary to sensitize the responses of α-cell
to hypoglycemia and the mechanism of the potential sensitiza-
tion of α-cells to insulin in diabetes. These results indicate that
SSTR2 blockade (Rossowski et al., 1998; Hocart et al., 1999) may
be a novel treatment strategy of improving counterregulatory
responses, including glucagon, to insulin-induced hypoglycemia.
This strategy could lead to prevention of hypoglycemia in insulin-
treated diabetics.
FUTURE DIRECTIONS
Considerable work investigating glucagon secretion and α-cell
signaling in healthy islets have been done as discussed above.
However, there has been relatively little progress in assess-
ing the perturbation of α-cellular physiology and paracrine
dysregulation during diabetes, which will require more innovative
approaches. One approach is the pancreatic slice preparation
(Huang et al., 2011a,b) whereby the α-cell and its precise
secretory physiology within intact pancreatic tissue could be
examined by patch-clamp technique, and perhaps later could
also be further assessed by imaging. The slice preparation has
very recently enabled us to begin to assess α-cell dysfunction
in T1D wherein the very small islet mass and inflammation
would have rendered it impossible to reliably isolate and exam-
ine the α-cell (Huang et al., 2012). In that report, α-cells in
STZ-induced diabetic mice exhibited enhanced Na+ currents
and reduced Kv currents, contributing to the increased action
potential amplitude and firing frequency. This, along with the
larger glucagon granules (found on E.M.) carrying larger amount
of glucagon cargo, would trigger more glucagon release, thus
explaining the basis of hyperglucagonemia in T1D (Huang et al.,
2012). Future studies employing the pancreas slice prepara-
tion will enable the elucidation of paracrine regulation within
normal and diabetic islets. Another approach is genetic manip-
ulation of candidate proteins within α-cells by α-cell-specific
knockout mouse models (Gustavsson et al., 2009; Kawamori
et al., 2009) and genetic β-cell ablation models mimicking T1D
(Thorel et al., 2010). Ideally, these clever approaches could be
combined.
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From a clinical point of view, the mechanism whereby in T2D
there is excessive response to glucagon during meals, and whether
pharmacological intervention can prevent this problem. A key
question is also whether it is possible to prevent hypoglycemia in
insulin-treated diabetics. So far, the evidence was obtained only
in STZ-treated and BB rats.
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